Combined androgen blockade in advanced prostate cancer: Looking back to move forward

Clinical Genitourinary Cancer

Volumn 5, Issue 6, 2007, Pages 371-378

  Chodak, Gerald ^a   Gomella, Leonard ^b   Phung, De H ^c  

^a WEISS MEMORIAL HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

First line therapy; Nonsteroidal antiandrogen therapy; Survival benefit; Tolerability

Indexed keywords

BICALUTAMIDE; BUSERELIN; CAPECITABINE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; IRINOTECAN; LEUPRORELIN; NAVELBINE; NILUTAMIDE; PLACEBO; TRASTUZUMAB;

ADVANCED CANCER; ARTERY DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG INHIBITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HEMATURIA; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS; ORCHIECTOMY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 35348840233     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2007.n.019     Document Type: Review

References (38)

1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424.
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036-1042.
3. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346:265-269.
4. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355:1491-1498.
5. Aus G, Abbou CC, Bolla M, et al. European Association of Urology guidelines on prostate cancer. Available at: http://www.uroweb.nl/files/ uploaded_files/2005Prostate%20Cancer.pdf. Accessed: December 19, 2005.
6. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93:1177-1182.
7. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. Urol Oncol 2004; 4:5-13.
8. Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1998; 1:307-314.
9. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22:2927-2941.
10. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997; 50:330-336.
11. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: the effects of castration on advanced carcinoma of the prostate cancer. Arch Surg 1941; 43:209-223.
12. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
13. The Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124:1011-1017.
14. Labrie F. Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am 1991; 20:845-872.
15. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95:361-376.
16. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57:727-732.
17. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341:418-422.
18. Klotz LH, Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Can J Urol 1996; 3:246-250.
19. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001; 87:806-813.
20. Bertagna C, de Géry A, Hucher M, et al. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994; 73:396-402.
21. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 1998; 33:144-151.
22. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34:20-28.
23. Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 2007; 10:194-201.
24. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141:26-32.
25. Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003; 22:239-264.
26. Aprikian AG, Fleshner N, Langleben A, et al. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. Can J Urol 2003; 10:1986-1994.
27. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92:1731-1739.
28. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596-1605.
29. Heidenreich A, Aus G, Abbou CC, et al. European Association of Urology guidelines on Prostate Cancer. Available at: http://www.uroweb.org/fileadmin/ user_upload/Guidelines/07_Prostate_Cancer_2007.pdf. Accessed September 19, 2007.
30. Migliari R, Muscas G, Murru M, et al. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 1999; 71:293-302.
31. Klotz L, Walker SE. Evaluating clinical and economic benefit for combination hormonal therapy in advanced prostate cancer. Eur J Hosp Pharm 2005; 11:47-49.
32. Autorino R, Perdona S, D'Armiento M, et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006; 9:109-114.
33. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 2006; 97:247-254.
34. Tyrrell CJ, Iversen P, Tammela T, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006; 98:563-572.
35. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90:1537-1544.
36. Naito S, Tachibana M, Deguchi T, et al. Addition of bicalutamide 80 mg to LHRH-agonist monotherapy in patients with advanced prostate cancer: impact on quality of life. Proc Am Soc Clin Oncol 2004; 23:430 (Abstract #4703).
37. Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and LHRH agonist in men with metastatic prostate cancer. J Urol 2005; 174:547-552.
38. Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005; 66:835-839.